LCT and Otsuka of Japan : Common DIABECELL ® Vision

April 12, 2011 ― Otsuka Pharmaceutical Factory, Inc. (head office: Naruto City, Tokushima, Japan; President: Ichiro Otsuka) (“OPF”) entered into a share subscription agreement on April 12, 2011 with Living Cell Technologies Limited (head office: Auckland, New Zealand, Managing Director & CEO：Ross Macdonald) (“LCT”) with respect to subscription for LCT’s new shares.
Under the agreement, OPF will invest AUD3 million in LCT for 25 million ordinary shares (A$0.12 per share). This investment will result in OPF holding 8.2% of LCT’s outstanding shares.
In addition to subscription for LCT’s new shares, OPF has earned an exclusive right to negotiate with LCT for research and development toward commercialization of LCT’s pancreatic islet “DIABECELL” and exclusive license and distribution right in Japan and other Asian countries (except for China).

It is OPF’s objective, through obtaining the rights for development and commercialization of this pancreatic islet DIABECELL, to offer additional therapeutic options for patients with diabetes, and to strengthen its R&D in the field of regenerative medicine and further actively expand its business not only in Japan but also on the international stage... [PDF] Otsuka Pharmaceutical Factory's Press Release - [PDF] Living Cell Technologies' Press Release -

LCT : Diabetes Clinical Trial

June 5, 2008 - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY) announced that the positive preliminary data from its first clinical trial of Diabecell® for insulin dependent type 1 diabetes has encouraged the Company to expand the trial and proceed with testing higher doses.
In LCT’s first Phase I/IIa trial of DiabeCell®, its lead product of encapsulated porcine insulin producing cells, 5 patients have been implanted with the lowest dose. As reported in the Company’s clinical update on 31 March 2008, there have been no significant adverse effects and a clinical effect was demonstrated with reduction in daily insulin requirement for up to six months follow up with satisfactory control of blood glucose... [PDF] Living Cell Technologies' Press Release -

Living Cell Technologies : Proprietary Nanobiocapsules at NZBio 2008

April 1, 2008 - Living Cell Technologies Limited (ASX: LCT) (PINKSHEETS: LVCLY) announced that Dr. Paul Tan, LCT CEO and Dr. Anil K. Anal, LCT Material Scientist, presented some data at a session on nanotechnology at the NZBio 2008 Conference in Auckland, New Zealand. Their presentation showcased the company's proprietary nanobiocapsules which allow encapsulated pig insulin producing cells, DiabeCell®, to be implanted without the use of toxic immune suppressive drugs.

On March 31, the Company reported positive early preliminary data from an on-going Phase I/IIa clinical trial which shows that following implant into patients with insulin dependent diabetes, the encapsulated porcine pancreatic islets remain functioning for at least 6 months and beneficial effects were greater than expected... LCT's Press Release -

Living Cell Technologies' DiabeCell Clinical Trial Program

February 26, 2008 - Living Cell Technologies Limited (ASX: LCT) (PINKSHEETS: LVCLY) announced that the Company has signed a term sheet with the Barbara Davis Center for Childhood Diabetes (BDC) to establish a diabetes clinical trial program in Denver, Colorado.
BDC and LCT will collaboratively pursue regulatory approval and then conduct a U.S. clinical trial in Type 1 diabetes with DiabeCell®, LCT's encapsulated porcine insulin producing cells. The proposed U.S. trial is planned to commence in 2009 and will be planned utilizing the clinical protocols and results from LCT's trials in Russia and New Zealand... [PDF] Living Cell Technologies' Press Release -

Living Cell Technologies, Positive Preliminary Data From DiabeCell® Phase I/IIa Trial in Type I Diabetes

October 9, 2007 - Living Cell Technologies Limited (ASX: LCT) released positive preliminary results for its Phase I/IIa clinical trial of the company's proprietary DiabeCell® porcine for the treatment of type 1 diabetes. The clinical trial is being conducted in six type 1 (insulin-dependent) diabetic patients... Living Cell Technologies' Press Release -

Living Cell Technologies, Ethics Approval for Diabetes Clinical Trial

12 September 2007 - Living Cell Technologies Ltd (ASX:LCT, OTC:LVCLY) is pleased to announce that it has obtained all the regulatory and ethics approvals required by the NZ Minister of Health before proceeding with its type 1 diabetes phase I/IIa clinical trial in New Zealand... Living Cell Technologies' Press release [PDF] -